Medications for Primary Prevention of Breast Cancer

JAMA. 2020 Jul 21;324(3):291-292. doi: 10.1001/jama.2020.9246.
No abstract available

Publication types

  • Review

MeSH terms

  • Anticarcinogenic Agents / adverse effects
  • Anticarcinogenic Agents / therapeutic use*
  • Aromatase Inhibitors / adverse effects
  • Aromatase Inhibitors / therapeutic use*
  • Breast Neoplasms / prevention & control*
  • Female
  • Humans
  • Primary Prevention / methods*
  • Raloxifene Hydrochloride / adverse effects
  • Raloxifene Hydrochloride / therapeutic use
  • Selective Estrogen Receptor Modulators / adverse effects
  • Selective Estrogen Receptor Modulators / therapeutic use*
  • Tamoxifen / adverse effects
  • Tamoxifen / therapeutic use
  • Uterine Neoplasms / chemically induced
  • Venous Thromboembolism / chemically induced

Substances

  • Anticarcinogenic Agents
  • Aromatase Inhibitors
  • Selective Estrogen Receptor Modulators
  • Tamoxifen
  • Raloxifene Hydrochloride